Clinical use of selective estrogen receptor modulators

Current Opinion in Rheumatology

Volumn 13, Issue 4, 2001, Pages 333-339

  Fontana, Aurélie ^a   Delmas, Pierre D ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

AGED; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; BREAST CARCINOMA; CANCER INCIDENCE; CANCER RISK; CATARACT; CLINICAL TRIAL; DISEASE PREDISPOSITION; DRUG MECHANISM; ENDOMETRIUM CARCINOMA; FEMALE; HOT FLUSH; HUMAN; MENOPAUSE; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; VERTEBRA FRACTURE;

BONE AND BONES; BONE DENSITY; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 0034841114     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200107000-00016     Document Type: Review

References (46)

1. The diagnosis of osteoporosis
2. The effect of postmenopausal estrogen therapy on bone density in elderly women
3. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer
4. Dual-energy x-ray absorptiometry of raloxifene effects on the lumbar vertebrae and femora of ovariectomized rats
5. Raloxifene (LY139481 HCL) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats
6. Raloxifene preserves bone strength and bone mass in ovariectomized rats
7. The short-term effects of tamoxifen on bone turnover in older women
8. Effects of tamoxifen and toremifene on urinary excretion of pyridinoline and deoxypyridinoline and bone density in postmenopausal patients with breast cancer
9. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients
10. A pilot trial to evaluate the acute toxicity and feasability of tamoxifen for prevention of breast cancer
11. Effect of tamoxifen on bone mineral density measured by dual energy x-ray absorptiometry in healthy premenopausal and postmenopausal women
12. Effects of tamoxifen on spinal bone density in women with breast cancer
13. Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: A randomized study
14. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
15. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years
16. Bisphosphonate Risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double blind, placebo-controlled study
17. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study
18. The effect of antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women
19. Tamoxifen for prevention of breast cancer: Report of the national surgical adjuvant breast and bowel project P-1 study
20. Controlled trial of raloxifene (LY139481)HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
21. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women
22. Effects of raloxifene on bone mineral density, serum cholesterolconcentrations, and uterine endometrium in postmenopausal women
23. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women
24. Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial
25. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene
26. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene
27. The effects of raloxifene on incident vertebral fractures in postmenopausal women with osteoporosis: 4-Year results from the MORE trial
28. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial
29. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women
30. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
31. The effect of raloxifene on the risk of breast cancer in postmenopausal women
32. Tamoxifen in the treatment of breast cancer
33. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial. Multiple outcomes of raloxifene evaluation
34. Cognitive function in postmenopausal women treated with raloxifene
35. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy
36. Consensus development conference: Diagnosis, prophylaxis and treatment of osteoporosis
37. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis
38. How antiresorptive therapy decrease the risk of fracture in women with osteoporosis?
39. Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
40. Pre-existing fractures and bone mass predict vertebral fracture incidence in women
41. Randomised trial of effects of alendronate on risk of fracture in women with existing vertebral fractures
42. Relationship between surface, volume and thickness of iliac trabecular bone in aging and in osteoporosis: Implication for the microanatomic and cellular mechanism of bone
43. Six months change in biochemical markers predict 3-year response in vertebral fracture rate in postmenopausal osteoporotic women: Results from the MORE study
44. Pretreatment BMD and vertebral fracture status as well as change in osteocalcin are all predictors for the risk of incident vertebral fracture during raloxifene therapy
45. A unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men
46. Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat